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Abstract Valine is one of the three branched-chain amino
acids which undergoes oxidation within mitochondria. In
this paper, we describe the current state of knowledge with
respect to the enzymology of the valine oxidation pathway
and the different disorders affecting oxidation.
Introduction
The three branched-chain amino acids (BCAA) leucine,
isoleucine, and valine are neutral amino acids, each with a
methyl-branch in the side chain. The human body is unable
to synthesize these amino acids de novo which implies that
the BCAAs are essential nutrients. Although they are
present in all protein-containing foods, the most prominent
sources are dairy products, red meat, whey and egg protein.
Most diets provide adequate amounts of these amino acids
amounting to 25–65 mg per kg body weight per day
(Young and Pellett 1985; Zello et al 1995).
Amino acid homeostasis in the human body is funda-
mentally different as compared to carbohydrate and lipid
homeostasis because carbohydrates can be stored in the
form of polysaccharides notably glycogen and lipids as
triglycerides. There is no separate storage form of amino
acids except as present in endogenous proteins. As a
consequence amino acid levels are the balanced result of
(1) dietary intake in the form of free amino acids and
proteins, (2) proteolysis of endogenous proteins, (3) de
novo synthesis, and (4) degradation. Since BCAAs cannot
be synthesized de novo, their homeostasis is maintained by
degradation and dietary intake only. Since BCAAs can be
degraded in multiple organs including skeletal muscle,
liver, kidney, heart, brain and adipose tissue, they can be
used as energy source, or utilized for biosynthetic purposes.
This includes the synthesis of lipids, since all three
catabolic pathways ultimately generate propionyl-CoA
and/or acetyl-CoA.
In humans, the BCAAs are metabolized in the
mitochondrion via the concerted action of a series of
enzymes. The starting point is the transport of BCAAs
via a sodium-dependent L-amino acid transporter across
the plasma membrane into the cells. Once in the
cytoplasm, the BCAAs can enter the mitochondrion in
two ways. First, the BCAAs can be transaminated in the
cytosol by the cytosolic branched-chain aminotransferase
followed by the subsequent transport of the resulting 2-
oxo-acids across the mitochondrial inner membrane via a
specific transporter protein. Alternatively, the BCAAs
can enter the mitochondrion as such via a neutral amino
acid carrier protein, and are then converted into the
different 2-oxo-acids by a mitochondrial aminotransfer-
ase. The contribution of the two different pathways has
remained ill-defined until now and may differ between
organs although the latter route appears to be preferred.
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two pathways then undergo oxidative decarboxylation by
the branched-chain 2-oxo-acid dehydrogenase complex
(BCKADH) to form the different branched-chain acyl-
CoA esters. This reaction is irreversible, similar to the
pyruvate dehydrogenase and 2-oxoglutarate dehydroge-
nase reactions.
Following these common steps, the degradative path-
ways for each of the different BCAAs diverge and
require the active participation of different enzymes
which are specific for each of the BCAAs. Remarkably,
the catabolic pathways of leucine, valine, and isoleucine
show analogy to the fatty acid oxidation pathway,
especially in the case of isoleucine which is degraded
via a 4-step mechanism involving subsequent steps of
dehydrogenation (via SBCAD), hydration (via croto-
nase), a second step of dehydrogenation catalyzed by
the enzyme 3-hydroxy-2-methylbutyryl-CoA dehydroge-
nase, alternatively named SCHMAD, MHBD, or ERAB,
as encoded by the HSD17B10 gene, and finally, thiolytic
cleavage via the K
+-dependent 2-methylacetoacetyl-CoA
specific thiolase. Oxidation of the isovaleryl-CoA derived
from leucine is completely different from that of the beta-
oxidation of acyl-CoAs except that the first step involves
the dehydrogenation of the substrate isovaleryl-CoA to 3-
methylcrotonyl-CoA via one of the acyl-CoA dehydro-
genases (ACADs) named isovaleryl-CoA dehydrogenase
(IVD).
The catabolic route of valine has remained enigmatic
not least because only a few defects in the pathway have
been described. One of the reasons for doubt remaining
about the true structure of the valine oxidation pathway
is that part of the pathway between 3-hydroxyisobutyryl-
CoA and propionyl-CoA has been claimed to proceed via
free acids, thus requiring the participation of a specific
hydrolase. Support for the involvement of such a
hydrolase has come from work of Brown et al 1982)
who identified a patient with 3-hydroxyisobutyryl-CoA
hydrolase deficiency. Definitive proof that the presumed
valine oxidation pathway (Fig. 1) is indeed correct has
come from our own work (Loupatty et al 2007)o nt h e
identification of 3-hydroxyisobutyryl-CoA hydrolase de-
ficiency in another patient, followed by the resolution of
the molecular defect in this newly identified patient and
the patient described by Brown et al (1982). Furthermore,
we recently identified the first patient with 3-
hydroxyisobutyric acid dehydrogenase deficiency (unpub-
lished observations) which provides final proof that the
valine degradation pathway as depicted in Fig. 1, is indeed
correct.
In this paper, an update is given on the enzymology of
the valine degradation pathway and the human disorders of
valine degradation.
Enzymology of the valine degradation pathway
Isobutyryl-CoA dehydrogenase. Protein: IBD; Gene:
ACAD8
Systematic studies by Tanaka and coworkers in the 1980s
using rat liver mitochondria as starting material have led to
the identification and purification of a new 2-methyl
branched-chain acyl-CoA dehydrogenase, which turned
out to be reactive with both 2-methylbutyryl-CoA and
isobutyryl-CoA, which are intermediates in the isoleucine
and valine degradation pathways, respectively (Ikeda and
Tanaka 1983a, b; Ikeda et al 1983). These data suggested
the involvement of a single enzyme in the valine and
isoleucine degradation pathways. More recently, the rat and
human cDNAs for this enzyme have been cloned and the
gene named short-branched-chain acyl-CoA dehydrogenase
(ACADSB). Recombinant rat SBCAD as produced in E.coli
turned out to be reactive with both isobutyryl-CoA and 2-
methylbutyryl-CoA in agreement with the results obtained
with the native enzyme isolated from rat liver mitochondria
by Ikeda and Tanaka (1983a). Surprisingly, however, the
recombinant human enzyme was only reactive with 2-
methylbutyryl-CoA and displayed little if any activity with
isobutyryl-CoA. These data suggested that, at least in the
human, distinct enzymes are involved in the oxidation of 2-
methylbutyryl-CoA and isobutyryl-CoA, respectively. Con-
clusive evidence for this notion has come from the
identification of patients with isolated deficiencies of 2-
methylbutyryl-CoA dehydrogenase and isobutyryl-CoA
dehydrogenase, respectively. Isolated 2-methylbutyryl-
CoA dehydrogenase deficiency was first reported by
Gibson et al (2000), followed by the resolution of the
molecular defect by Andresen et al (2000) whereas isolated
isobutyryl-CoA dehydrogenase deficiency was first
reported in 1998 by Roe et al (1998a). Elaborating on
work by Telford et al (1999) ,w h i c hh a dl e dt ot h e
identification of a novel cDNA coding for a new member
of the ACAD-family (ACAD8), Nguyen et al (2002)
expressed the ACAD8 cDNA in E.coli and established that
the human recombinant enzyme had highest activity with
isobutyryl-CoA (Km=2.6 μmol/L; kcat=2.0±0.14) although
(S)-2-methylbutyryl-CoA also turned out to be a relatively
good substrate (Km=18 μmol/L; kcat=4.1±0.3).
Methacrylyl-CoA hydratase
The next step in the valine degradation pathway involves
the hydration of methacrylyl-CoA to 3-hydroxyisobutyryl-
CoA. Although methacrylyl-CoA can apparently undergo
non-enzymatic hydration to 3-hydroxyisobutyryl-CoA
(Bachhawat et al 1957; Redina and Coon 1957) in aqueous
solution, the generally accepted idea is that under in vivo
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occurs enzymatically. Early work had already shown that
the enzyme short-chain enoyl-CoA hydratase as isolated
from bovine liver, which is also named crotonase (gene :
ECHS1) can hydrate methacrylyl-CoA to 3-
hydroxyisobutyryl-CoA (Jr and Del 1956; Steinman and
Hill 1975). Studies in human liver sonicates have shown
that hydration of methacrylyl-CoA occurs at a 15-fold
lower rate compared with crotonyl-CoA as substrate
(Brown et al 1982).
3-Hydroxyisobutyryl-CoA hydrolase (HIBCH)
Originally, it seemed paradoxical that an acyl-CoA hydro-
lase should be required for the degradation of valine
especially since both the proximal as well as distal parts
of the pathway involve coenzyme A ester intermediates.
Redina and Coon (1957), however, identified an enzyme in
pig heart converting 3-hydroxyisobutyryl-CoA (HIBYL-
CoA) to 3-hydroxyisobutyric acid, and partially purified the
enzyme. Many years later, Shimomura et al (1994) reported
Fig. 1 Schematic representation
of the valine oxidation pathway
and the enzymes involved (see
text)
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homogeneity. The purified hydrolase had a molecular
weight of 36 kDa and appeared to be a monomer. The
enzyme turned out to have a very limited substrate
preference only accepting 3-hydroxypropionyl-CoA as
alternative substrate at 57% of the rate compared to
HIBYL-CoA. The availability of the purified rat liver
enzyme allowed cloning of the human enzyme. The
human enzyme is made up of 352 amino acids with a
28-amino-acid mitochondrial leader sequence, reacts with
S-3-hydroxyisobutyryl-CoA and 3-hydroxypropionyl-CoA
with virtually no reactivity towards other acyl-CoAs, and
is expressed in multiple tissues as established by immu-
noblot analysis. The tissue distribution is: liver = kidney >
heart >> muscle = brain.
3-Hydroxyisobutyric acid dehydrogenase (HIBADH)
Robinson and Coon were the first to isolate and characterize a
3-hydroxyisobutyratedehydrogenase activityfrompigkidney
subsequentlyfollowed bythe isolation and characterization of
this enzyme from various organisms (Robinson and Coon
1957; Hawes et al 1996, 2000;R o u g r a f fe ta l1988, 1989). In
1989, cloning of the rat cDNA for this enzyme was reported
(Rougraff et al 1989). In 2006, we reported the successful
cloning of the human HIBADH cDNA and its expression in
E.coli, followed by kinetic studies to pinpoint the Km-values
for (S)-3-hydroxyisobutyrate and NAD
+ (Loupatty et al
2006).
Methylmalonic semialdehyde dehydrogenase (MMSDH)
The next enzyme in the valine degradation pathway
converts methylmalonic semialdehyde to propionyl-CoA.
The enzyme was first purified from bacteria (Bannerjee
et al 1970) and subsequently purified from rat liver by
Harris and coworkers (Bannerjee et al 1970). The
monomer molecular mass determined by SDS-PAGE
was 58 kDa whereas the native molecular mass as
determined by gel filtration was 250 kDa suggesting a
tetramer of four 58-kDa subunits (Gibson et al 1993;
Zhang et al 1996).
The enzyme also acts on malonic semialdehyde as derived
from the catabolism of uracil. Furthermore, both S-methyl-
malonic semialdehyde as well as R-methylmalonic semi-
aldehyde are handled by the enzyme suggesting that a single
enzyme is involved in the catabolism of valine, thymine as
well as uracil. The rat liver cDNA for MMSDH has
subsequently been cloned and sequenced by Kedishvili et
al (1992).
The subsequent enzymes involved in the transformation
of propionyl-CoA are shared with the isoleucine pathway
and will not be discussed here.
Inborn errors of valine degradation
So far, relatively few patients have been identified with a
defect in the valine degradation pathway. Furthermore, all
the disorders in the valine degradation pathway known until
now have been identified in symptomatic patients, except
for IBD-deficiency for which additional patients have been
identified through newborn screening. None of the other
disorders have yet been identified through newborn
screening and so information on the full spectrum of
disease is unavailable. Moreover, most of the disorders
have had inconsistent symptoms in reported patients as
discussed below.
Isobutyryl-CoA dehydrogenase deficiency
Isolated isobutyryl-CoA dehydrogenase deficiency was first
described by Roe et al (1998a)a s“an unrecognized defect in
human valine metabolism” in a 2-year-old female who was
well until 12 months of age and was then found to be anemic
with cardiomyopathy in addition. Acylcarnitine analyses
revealed elevated C4-carnitine and a low free carnitine level
(6 μmol/L) whereas urinary organic acids were normal.
Subsequently, in vitro oxidation studies were done in
fibroblasts using 16,16,16-
2H3-palmitate, U-
13C-L-valine,
U-
13C-L-leucine and U-
13C-L-isoleucine as substrates. Ox-
idation of all substrates except
13C5-valine was normal.
Upon incubation with
13C5-valine a significant increase in
13C4-isobutyrylcarnitine was found without any incorpora-
tion of label into propionylcarnitine as observed in control
cells. These results led Roe et al (1998a) to conclude that “in
the human, there is a distinct isobutyryl-CoA dehydrogenase
which exists as a separate enzyme serving only the valine
pathway”. Subsequent studies by Nguyen et al (2002)h a v e
led to the realization that a previously uncharacterized
ACAD-like sequence (ACAD8)i sa c t u a l l yc o d i n gf o ra
dehydrogenase with isobutyryl-CoA as preferred substrate.
Mutation analysis of the cDNA prepared from the fibroblasts
of the patient identified by Roe et al (1998a), revealed a
homozygous single nucleotide change (c.905 G>A) causing
an arginine to glutamine substitution at position 302
(Arg302Gln). The mutant enzyme was stable but turned
o u tt ob ei n a c t i v ew h e ne x p r e s s e di nE.coli. Since the
description of the first case by Roe et al (1998a)m a n y
additional cases have been reported (Koeberl et al 2003;S a s s
et al 2004; Pedersen et al 2006; Oglesbee et al 2007). Most
cases have been identified in the extended neonatal screening
programs, notably in the US. Indeed, Oglesbee et al (2007)
have reported on the identification of 13 patients through
neonatal screening, only 1 of whom was symptomatic.
Furthermore, Oglesbee et al (2007) developed a newborn
s c r e e n i n gf o l l o wu pa l g o r ithm for the diagnosis of
isobutyryl-CoA dehydrogenase deficiency.
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four patients identified by newborn screening as well as the
patients described in literature by Roe et al (1998a), Nguyen
et al (2002), Sass and Sperl (2001) and Battaile et al (2004).
The diagnosis IBD-deficiency was substantiated by urine
analysis (isobutyrylglycine), and in vitro probe analysis
using
13C5-valine but not by enzyme studies, simply because
at present there is no reliable enzyme assay for isobutyryl-
CoA dehydrogenase, at least in fibroblasts and lymphocytes.
Molecular analysis revealed mutations in all eight patients.
No common mutations were identified. Interestingly, the
mutations found all produce amino acid substitutions.
Expression studies in Chang cells by Pedersen et al (2006)
revealed disturbed protein folding and reduced levels of
correctly folded IBD tetramers, and markedly decreased
enzyme activities.
Patient identification and characterization using metabolite,
enzyme and molecular studies
Ideally IBD-deficiency can be diagnosed by combined
analysis in plasma (acylcarnitine analysis) and urine
(organic acid analysis) showing elevated C4-carnitine and
marginally increased isobutyrylglycine. Indeed, increased
plasma C4-carnitine and urine isobutyrylglycine have been
demonstrated in most, but definitely not all patients. The
first patient described by Roe et al. had elevated plasma C4-
carnitine for instance, but normal urinary isobutyrylglycine.
Of the four cases picked up by neonatal screening by
Pedersen et al (2006), three had elevated C4-carnitine plus
elevated urinary isobutyrylglycine, but one had elevated
C4-carnitine only with normal urinary isobutyrylglycine.
One possibility is to perform MS/MS-analysis coupled with
HPLC or UPLC to separate butyryl- and isobutyryl-
carnitine. Methods to achieve this have been published.
As described above, there are no reports on IBD-activity
measurements in fibroblasts or other readily available cells
including lymphocytes. In our hands, IBD-activity in
fibroblasts is too low to allow reliable measurement of
IBD-activity. The absence of reliable enzymatic methods
has prompted molecular analysis of the ACAD8-gene
followed by expression studies in Chang cells, for instance
as done by Pedersen et al (2006).
3-Hydroxyisobutyryl-CoA hydrolase deficiency
So far, only two patients with 3-hydroxyisobutyryl-CoA
hydrolase deficiency as established by enzymatic and
molecular methods have been identified. The first patient
described by Brown et al (1982) had dysmorphic features
at birth, poor feeding, failure to thrive, lack of develop-
ment of motor skills, hypotonia and absence of neurologic
development. The infant died at 3 months. Other findings
included vertebral abnormalities, tetralogy of Fallot, and
agenesis of the cingulate gyrus and corpus callosum. The
biochemical basis of 3-hydroxyisobutyryl-CoA hydrolase
deficiency was resolved in the early 1980s after the
finding of elevated urinary levels of S-2-carboxypropyl-
cysteïne and S-2-carboxypropyl-cysteamine. These deriv-
atives are formed through the addition of cysteine and
cysteamine across the carbon-carbon double bond of
methacrylyl-CoA. Subsequently, the activity of 3-
hydroxyisobutyryl-CoA hydrolase was measured, using a
coupled enzyme assay in which methacrylyl-CoA was
used in the presence of an excess of crotonase. Brown and
coworkers demonstrated a 20% residual activity of 3-
hydroxyisobutytyl-CoA hydrolase in cultured skin fibro-
blasts. Using an optimized enzyme assay, we detected no
residual activity in fibroblasts from this patient, however
(Loupatty et al. 2007).
The second patient, described by us, was the first
child of healthy non-consanguineous Caucasian parents
and was born at term, following an uneventful pregnan-
cy. Initially, he fed poorly, but otherwise appeared well
until 4 months of age when his parents noted head
bobbing. This was followed by a delay in motor
milestones, then ataxia and a loss of skills. He was able
to roll over at 5 months but lost this ability at 10 months.
He was reaching out and grasping objects at 4 months,
but gradually lost this skill at 13 months. From the age
of 9 months, he started to have transient absences and
episodes of eye rolling. At the age of 10 months, he had
a febrile illness during which he became irritable and
more wobbly. He lost the ability to finger feed.
Examination at 11 months revealed an alert interactive
child with no nystagmus but constant titubation of the
head. He had marked truncal ataxia and was unable to sit
unsupported. Tone, power and reflexes were normal in
the upper limbs. Tone was reduced, particularly distally
in the lower limbs. He had marked dysmetria and tremor
on reaching out. At the age of 14 months, following
2 days of coryza and lethargy, he became acutely unwell
with a reduced level of consciousness and metabolic
acidosis, which required intubation and ventilatory
support. Blood pH was 7.29 with a base deficit of
15.8 mmol/L. Blood lactate and ammonia were normal.
Echocardiography demonstrated no abnormalities. Exam-
ination following recovery from this illness showed
drowsiness, variable nystagmus, sluggish papillary
responses, pooling of secretions in the mouth, fascicula-
tion of the tongue, titubation of the head, and upper and
lower limb hypotonia with preservation of reflexes. He
showed no improvement on treatment with thiamine or a
combination of vitamin C, vitamin E and ubiquinone. As
he recovered from this episode of acute encephalopathy
he developed dystonia predominantly affecting the right
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acute encephalopathy, revealed generalized edema of the
brain with loss of gray/white differentiation in the basal
ganglia. In addition, an MRI scan revealed signal
abnormalities in the globus pallidus and the midbrain
with asymmetrical involvement of the cerebral peduncles
(right greater than left). No structural abnormalities of
the brain were observed. As the neuroimaging was
reminiscent of Leigh’s disease, initial investigations were
performed focused on pyruvate dehydrogenase, pyruvate
carboxylase, and the respiratory chain, which revealed no
abnormalities, except for a marked reduction of complex
I and a borderline reduction in complex IV. Remarkably,
elevated levels of hydroxy-C4 carnitine were found in
blood spots of the patient, ranging between 0.45 and
1.73 μmol/L (controls <0.4 μmol/L). Based on the
elevation of hydroxy-C4 carnitine the activity of short-
chain 3-hydroxyacyl-CoA dehydrogenase was measured,
which was normal. Subsequently, the activity of 3-
hydroxyisobutyryl-CoA hydrolase was measured which
revealed a full deficiency (see Loupatty et al 2007)).
Molecular studies in the two patients described by Brown
et al (1982) and Loupatty et al (2007), respectively,
revealed clear-cut mutations in the gene coding for 3-
hydroxyisobutyryl-CoA hydrolase.
Except for these two patients, no additional patients with
this defect have been described.
3-Hydroxyisobutyrate-CoA dehydrogenase deficiency
3-Hydroxyisobutyric aciduria is a rare organic aciduria and
to date only some ten patients have been described in the
literature (Ko et al 1991; Chitayat et al 1992; Boulat et al
1995; Sasaki et al 1998, 2001; Shield et al 2001). These
patients usually present with dysmorphic features including
a small triangular face, low set ears, long philtum and
microcephaly. Patients may show widely different pheno-
types ranging from mild vomiting attacks with normal brain
and cognitive development, to delayed motor development,
profound mental retardation and early death. Patients with
3-hydroxyisobutyric aciduria usually excrete elevated
amounts of 3-hydroxyisobutyric acid in urine ranging from
60 to 390 mmol/mol creatinine (normal <40 mmol/mol
creatinine). In half of the reported cases, elevated lactate
levels have been observed. We have studied these patients
as well as two novel patients with 3-hydroxyisobutyric
aciduria. Enzyme activity measurements revealed no
abnormalities in fibroblasts from these patients. In addition
to that, molecular analysis of the human gene coding for 3-
hydroxyisobutyrate dehydrogenase revealed no abnormali-
ties as well. Very recently we identified the first case of 3-
hydroxyisobutyrate dehydrogenase deficiency in a patient
with 3-hydroxyisobutyric aciduria.
Methylmalonic semialdehyde dehydrogenase deficiency
Although several patients with presumed methylmalonic
semialdehyde dehydrogenase deficiency have been described
in the literature (Gibson et al 1993;K oe ta l1991;G r a ye ta l
1987; Pollitt et al 1985; Roe et al 1998b), only a single
patient with genetically proven methylmalonic semialdehyde
dehydrogenase deficiency has been described in the literature
so far (Gray et al 1987; Pollitt et al 1985; Chambliss et al
2000). Routine newborn screening demonstrated a marked
hypermethioninemia. The male patient was hospitalized at
the age of 3 weeks with an unexplained episode of diarrhea
and vomiting. Subsequent urinary organic acid analysis
revealed extremely elevated levels of 3-hydroxyisobutyric
acid. Further investigations also demonstrated increased
urinary excretion of beta-alanine, 3-hydroxypropionic acid,
and both isomers of 3-aminoisobutyric acid, suggesting
methylmalonic semialdehyde dehydrogenase deficiency.
Molecular analysis of the human MMSDH gene revealed
homozygosity for a missense mutation (c.1336 G >A;
G446R) (Pollitt et al 1985). No expression studies were
performed with the mutant cDNA.
Valine degradation disorders and newborn screening
In various countries around the world, at least some of the
valine degradation disorders have been included in neonatal
screening programs. For some of these disorders algorithms
have been developed to be used in the follow-up of cases
picked up by newborn screening as described by Oglesbee
et al (2007) for isobutyryl-CoA dehydrogenase deficiency.
Most, if not all the enzymes involved in the valine
oxidation pathway are also expressed in blood cells,
including lymphocytes, which indicates that there might
also be a place for enzymatic analysis in the follow-up of
cases picked up by newborn screening. We are currently
studying the feasibility of using enzymatic methods for this
purpose.
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